Literature DB >> 28721302

Correlation between two methods of florbetapir PET quantitative analysis.

Christopher Breault1,2, Jonathan Piper3, Abhinay D Joshi1, Sara D Pirozzi3, Aaron S Nelson3, Ming Lu1, Michael J Pontecorvo1, Mark A Mintun1, Michael D Devous1.   

Abstract

This study evaluated performance of a commercially available standardized software program for calculation of florbetapir PET standard uptake value ratios (SUVr) in comparison with an established research method. Florbetapir PET images for 183 subjects clinically diagnosed as cognitively normal (CN), mild cognitive impairment (MCI) or probable Alzheimer's disease (AD) (45 AD, 60 MCI, and 78 CN) were evaluated using two software processing algorithms. The research method uses a single florbetapir PET template generated by averaging both amyloid positive and amyloid negative registered brains together. The commercial software simultaneously optimizes the registration between the florbetapir PET images and three templates: amyloid negative, amyloid positive, and an average. Cortical average SUVr values were calculated across six predefined anatomic regions with respect to the whole cerebellum reference region. SUVr values were well correlated between the two methods (r2 = 0.98). The relationship between the methods computed from the regression analysis is: Commercial method SUVr = (0.9757*Research SUVr) + 0.0299. A previously defined cutoff SUVr of 1.1 for distinguishing amyloid positivity by the research method corresponded to 1.1 (95% CI = 1.098, 1.11) for the commercial method. This study suggests that the commercial method is comparable to the published research method of SUVr analysis for florbetapir PET images, thus facilitating the potential use of standardized quantitative approaches to PET amyloid imaging.

Entities:  

Keywords:  Amyloid imaging; PET quantitation; amyloid PET; amyvid; florbetapir

Year:  2017        PMID: 28721302      PMCID: PMC5511118     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  25 in total

1.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

2.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study.

Authors:  Claudia H Kawas; Dana E Greenia; Szofia S Bullain; Christopher M Clark; Michael J Pontecorvo; Abhinay D Joshi; María M Corrada
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

5.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

6.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

7.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

8.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

9.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

Review 10.  A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.

Authors:  Daniela Perani; Perani Daniela; Orazio Schillaci; Schillaci Orazio; Alessandro Padovani; Padovani Alessandro; Flavio Mariano Nobili; Nobili Flavio Mariano; Leonardo Iaccarino; Iaccarino Leonardo; Pasquale Anthony Della Rosa; Della Rosa Pasquale Anthony; Giovanni Frisoni; Frisoni Giovanni; Carlo Caltagirone; Caltagirone Carlo
Journal:  Biomed Res Int       Date:  2014-03-19       Impact factor: 3.411

View more
  4 in total

1.  Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy.

Authors:  Kei Wagatsuma; Kenji Ishibashi; Masashi Kameyama; Muneyuki Sakata; Kenta Miwa; Yuto Kamitaka; Kenji Ishii
Journal:  Radiol Phys Technol       Date:  2022-03-03

Review 2.  What's the cut-point?: a systematic investigation of tau PET thresholding methods.

Authors:  Alexandra J Weigand; Anne Maass; Graham L Eglit; Mark W Bondi
Journal:  Alzheimers Res Ther       Date:  2022-04-05       Impact factor: 8.823

3.  Blunted cerebrovascular response is associated with elevated beta-amyloid.

Authors:  Jason-Flor V Sisante; Eric D Vidoni; Kiersten Kirkendoll; Jaimie Ward; Yumei Liu; Sarah Kwapiszeski; Rebecca Maletsky; Jeffrey M Burns; Sandra A Billinger
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-15       Impact factor: 6.200

4.  Differences among [18F]FDG PET-derived parameters in lung cancer produced by three software packages.

Authors:  Agnieszka Bos-Liedke; Paulina Cegla; Krzysztof Matuszewski; Ewelina Konstanty; Adam Piotrowski; Magdalena Gross; Julian Malicki; Maciej Kozak
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.